← Back to Treatments
🏅 FDA Orphan Designation

Ryplazim

plasminogen, human-tvmh

Manufacturer: ProMetic BioTherapeutics, Inc.

Indicated for:
Tyrosinemia type 2OrphanHypoplasminogenemiaOrphan

FDA-Approved Indications (2)

Tyrosinemia type 2Orphan Designation

Treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia).

HypoplasminogenemiaOrphan Designation

Treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia)

Population: all ages

Indications & Usage

Treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia).

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.